Roche, Trimeris withdraw application for Fuzeon injection device

10/3/2007 | News & Observer (Raleigh, N.C.), The · Forbes

Roche Holding subsidiary Hoffmann-La Roche and Trimeris said they are withdrawing their FDA application to market the Biojector 2000 needle-free injection device in combination with HIV drug Fuzeon, following a comprehensive evaluation of a clinical trial and a delay in getting regulatory approval. The companies believe the device isn't an ideal substitute for the delivery of the drug among "all treatment-experienced patients" despite its potential benefits, a Roche official said.

View Full Article in:

News & Observer (Raleigh, N.C.), The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ